South Korean biotechnology company LOTTE BIOLOGICS announced on Thursday that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a UK-based biopharmaceutical company developing PD1/VEGFR2 dual pathway antibodies to treat cancer.

The signing ceremony took place at the LOTTE BIOLOGICS booth within the Boston Convention and Exhibition Center, where BIO INTERNATIONAL 2025 is being held. Through this agreement, LOTTE BIOLOGICS will produce antibody drug substance for Ottimo Pharma's Jankistomig at its Syracuse Bio Campus in New York.

LOTTE BIOLOGICS currently provides CDMO services at its Syracuse Bio Campus, ranging from cell line development to large-scale contract manufacturing of biopharmaceuticals. Additionally, the company says that it aims to begin operation of Plant 1 at its Songdo Bio Campus in 2027. Plant 1 will be a large-scale biopharmaceutical manufacturing facility with a production capacity of 120,000 litres, enabling the company to handle major global contracts.

To provide client-specific end-to-end services, LOTTE BIOLOGICS has entered strategic collaborations with global contract development organisations (CDOs) and drug product (DP) companies. Through these partnerships, it offers fully customised CDMO solutions spanning early drug development to commercialisation.